Virtual Library

Start Your Search

Nahoko Shimizu



Author of

  • +

    EP1.12 - Small Cell Lung Cancer/NET (ID 202)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Small Cell Lung Cancer/NET
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.12-17 - Neuroendocrine Marker Staining Pattern Categorization of Small-Sized Pulmonary Large Cell Neuroendocrine Carcinoma (Now Available) (ID 677)

      08:00 - 18:00  |  Author(s): Nahoko Shimizu

      • Abstract
      • Slides

      Background

      Pulmonary large cell neuroendocrine carcinoma (LCNEC) is categorized as high-grade neuroendocrine carcinoma and is known to be associated with shorter survival than that of other non-small cell lung cancers.

      Radical therapies for these tumors are considered to have limited applicability to small-sized cases because of their rapid growth and early metastasis.

      The study aim was to identify subgroups with good or bad prognosis in patients with small-sized LCNEC (sLCNEC) that were based on immunostaining patterns with neuroendocrine markers.

      Method

      From January 2001 to December 2017, of all patients with surgically resected LCNEC, we selected patients whose pathological tumor sizes were ≤30 mm in diameter (defined as small-sized tumors) and who underwent complete anatomical resection with hilar and mediastinal lymphadenectomy. We classified patients with sLCNEC into 2 subgroups based on immunostaining patterns with 3 neuroendocrine makers (chromogranin A, synaptophysin, and neural-cell adhesion molecule).

      Result

      Forty-eight patients with sLCNEC were enrolled in this study. Of 48 patients with sLCNEC, 21 were categorized as the small-sized triple-positive group (sTP), whose patients were positive for the 3 neuroendocrine markers, and 27 patients were categorized as the small-sized non-triple-positive group (sNTP), whose patients were not positive for all 3 neuroendocrine markers. Table 1 shows cliniopathological characteristics among sNTP and sTP. The percentage of lymph node metastasis was significantly lower in sNTP than in sTP (11% and 48%, respectively, P< 0.01). There was no significant difference in overall survival, but recurrence-free survival (RFS) and tumor-specific survival (TSS) were significantly poorer in sTP than in sNTP (Fig 1). Multivariate analysis using 6 clinical factors (age, sex, surgical procedure, pN status, histology, and adjuvant chemotherapy) revealed that sTP were independent prognostic factors for poorer RFS and TSS than those of sNTP.

      table 1.jpgfig 1.jpg

      Conclusion

      The sNTP subgroup had good prognosis and the sTP subgroup had poor prognosis.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.